323 related articles for article (PubMed ID: 29084080)
1. Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.
Gawronska A; Banasiuk M; Lachowicz D; Pituch H; Albrecht P; Banaszkiewicz A
Inflamm Bowel Dis; 2017 Dec; 23(12):2209-2214. PubMed ID: 29084080
[TBL] [Abstract][Full Text] [Related]
2. Clostridium difficile infection and inflammatory bowel disease: what gastroenterologists and surgeons should know.
Cojocariu C; Trifan A; Stoica O; Chihaia CA; Stanciu C
Chirurgia (Bucur); 2014; 109(5):579-83. PubMed ID: 25532244
[TBL] [Abstract][Full Text] [Related]
3. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
Hughes M; Qazi T; Berg A; Weinberg J; Chen X; Kelly CP; Farraye FA
Inflamm Bowel Dis; 2016 Apr; 22(4):853-61. PubMed ID: 26954708
[TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study.
Sokol H; Lalande V; Landman C; Bourrier A; Nion-Larmurier I; Rajca S; Kirchgesner J; Seksik P; Cosnes J; Barbut F; Beaugerie L
Dig Liver Dis; 2017 Jun; 49(6):643-646. PubMed ID: 28215602
[TBL] [Abstract][Full Text] [Related]
5. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
Vitikainen K; Haapamäki J; Färkkilä M; Anttila VJ; Arkkila P
Scand J Gastroenterol; 2018 Aug; 53(8):947-951. PubMed ID: 30041549
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.
Khoruts A; Rank KM; Newman KM; Viskocil K; Vaughn BP; Hamilton MJ; Sadowsky MJ
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1433-8. PubMed ID: 26905904
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series.
Neff G; Zacharias V; Kaiser TE; Gaddis A; Kemmer N
Liver Transpl; 2010 Aug; 16(8):960-3. PubMed ID: 20677286
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.
Garey KW; Ghantoji SS; Shah DN; Habib M; Arora V; Jiang ZD; DuPont HL
J Antimicrob Chemother; 2011 Dec; 66(12):2850-5. PubMed ID: 21948965
[TBL] [Abstract][Full Text] [Related]
9. Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.
Lukin DJ; Lawlor G; Hudesman DP; Durbin L; Axelrad JE; Passi M; Cavaliere K; Coburn E; Loftus M; Jen H; Feathers A; Rosen MH; Malter LB; Swaminath A;
Inflamm Bowel Dis; 2019 Mar; 25(4):775-781. PubMed ID: 30312400
[TBL] [Abstract][Full Text] [Related]
10. Case-Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus.
Li Y; Xu H; Xu T; Xiao M; Tang H; Wu D; Tan B; Li J; Yang H; Lv H; Xu Y; Qian J
Dig Dis Sci; 2018 Nov; 63(11):3074-3083. PubMed ID: 30094621
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin in the treatment of recurrent Clostridium difficile infection.
Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
[TBL] [Abstract][Full Text] [Related]
12. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease.
Wultańska D; Banaszkiewicz A; Radzikowski A; Obuch-Woszczatyński P; Młynarczyk G; Brazier JS; Pituch H; van Belkum A
Eur J Clin Microbiol Infect Dis; 2010 Oct; 29(10):1265-70. PubMed ID: 20577773
[TBL] [Abstract][Full Text] [Related]
13. Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield.
Deshpande A; Pasupuleti V; Patel P; Pant C; Pagadala M; Hall G; Hu B; Jain A; Rolston DD; Sferra TJ; Atreja A
Curr Med Res Opin; 2012 Sep; 28(9):1553-60. PubMed ID: 22852871
[TBL] [Abstract][Full Text] [Related]
14. Fecal Microbiota Transplantation in Recurrent NAP1/B1/027 Clostridium Difficile Infection (CDI) Resistant to Vancomycin and Metronidazole in a Patient with Ulcerative Colitis (UC): A Case Report.
Preda CM; Meianu C; Sandra I; Becheanu G; Dumbrava M; Manuc M; Diculescu M
Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):563-7. PubMed ID: 30044904
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children.
Parmar D; Dang R; Miranda-Katz M; Alabaster A; Greenhow TL
Pediatr Infect Dis J; 2019 Nov; 38(11):1073-1078. PubMed ID: 31626042
[TBL] [Abstract][Full Text] [Related]
16. Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease.
Horton HA; Dezfoli S; Berel D; Hirsch J; Ippoliti A; McGovern D; Kaur M; Shih D; Dubinsky M; Targan SR; Fleshner P; Vasiliauskas EA; Grein J; Murthy R; Melmed GY
Antimicrob Agents Chemother; 2014 Sep; 58(9):5054-9. PubMed ID: 24913174
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
[TBL] [Abstract][Full Text] [Related]
18. Management of inflammatory bowel disease with
D'Aoust J; Battat R; Bessissow T
World J Gastroenterol; 2017 Jul; 23(27):4986-5003. PubMed ID: 28785153
[TBL] [Abstract][Full Text] [Related]
19. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
20. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
El-Herte RI; Baban TA; Kanj SS
Scand J Infect Dis; 2012 Mar; 44(3):228-30. PubMed ID: 22077098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
